Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will be conducted in subjects with clinical diagnosis of worsening chronic heart failure and either type 2 diabetes mellitus (DM) with or without chronic kidney disease (CKD) or moderate CKD alone treated with evidence-based therapy for heart failure (HF) for at least 3 months prior to emergency presentation to hospital using a multi-center, randomized, adaptive, double-blind, double-dummy, comparator-controlled, parallel-group design.
Primary objective of the study is to investigate efficacy [percentage of subjects with a relative decrease in N-terminal prohormone B-type natriuretic peptide (NT-proBNP) of more than 30% from baseline to Visit 10 (Day 90)] and safety of different oral doses of BAY94-8862 given once daily.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| BAY94-8862 (2.5 mg) | Experimental | 2.5 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 5 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium |
|
| BAY94-8862 (5 mg) | Experimental | 5 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 10 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium |
|
| Eplerenone | Active Comparator | 25 mg eplerenone every other day, i.e. one 25 mg eplerenone capsule on Day 1, Day 3, Day 5, etc. in the morning, 1 placebo capsule on Day 2, Day 4, Day 6, etc. in the morning, and 1 placebo tablet once daily in the morning, with possible up-titration to 25 mg eplerenone once daily at Visit 6 (Day 30), i.e. one 25 mg eplerenone capsule once daily in the morning and 1 placebo tablet once daily in the morning, and a possible up-titration to 25 mg once daily [if not performed at Visit 6 (Day 30)] or to 50 mg once daily [if up-titrated to 25 mg once daily at Visit 6 (Day 30)] at Visit 8 (Day 60), based on the value of blood potassium |
|
| BAY94-8862 (7.5 mg) | Experimental | 7.5 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 15 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium Note: This treatment group may be introduced into the study or not after safety and tolerability of these doses has been assessed by an independent Data Monitoring Committee (DMC) (1st dose recommendation DMC meeting). |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BAY94-8862 | Drug | 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg of BAY94-8862 tablets |
|
| Measure | Description | Time Frame |
|---|---|---|
| The percentage of subjects with a relative decrease in N-terminal prohormone B-type natriuretic peptide of more than 30% from baseline to Visit 10 | From baseline to 90 days |
| Measure | Description | Time Frame |
|---|---|---|
| Change in serum potassium | From baseline to 90 days |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bayer Study Director | Bayer | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Seto | Aichi-ken | 489-8642 | Japan | |||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 27074824 | Result | Sato N, Ajioka M, Yamada T, Kato M, Myoishi M, Yamada T, Kim SY, Nowack C, Kolkhof P, Shiga T; ARTS-HF Japan study group. A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease. Circ J. 2016 Apr 25;80(5):1113-22. doi: 10.1253/circj.CJ-16-0122. Epub 2016 Apr 14. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| BAY94-8862 (10 mg) | Experimental | 10 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 20 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium Note: Only in case the above mentioned additional treatment arm (BAY94-8862, 7.5 mg) has been added, a second dose decision meeting of the DMC will take place, Again safety and tolerability of all doses will be assessed by an independent DMC (2nd dose recommendation DMC meeting). Based on this data, none or up to two treatment groups (BAY94-8862, 10 mg and BAY94-8862,15 mg) may be introduced into the study. |
|
| BAY94-8862 (15 mg) | Experimental | 15 mg BAY94-8862 tablet and placebo capsule once daily in the morning, with possible up-titration to 20 mg once daily at Visit 6 (Day 30), and sham up-titration at Visit 8 (Day 60), based on the value of blood potassium Note: Only in case the above mentioned additional treatment arm (BAY94-8862, 7.5 mg) has been added, a second dose decision meeting of the DMC will take place, Again safety and tolerability of all doses will be assessed by an independent DMC (2nd dose recommendation DMC meeting). Based on this data, none or up to two treatment groups (BAY94-8862, 10 mg and BAY94-8862,15 mg) may be introduced into the study. |
|
| Eplerenone | Drug | INSPRA 25 and 50 mg tablets (MAH: Pfizer) will be used for eplerenone 25 and 50 mg tablets |
|
| Placebo | Drug | matching placebo |
|
| Toyota |
| Aichi-ken |
| 471-8513 |
| Japan |
| Funabashi | Chiba | 273-8588 | Japan |
| Kamogawa | Chiba | 296-8602 | Japan |
| Matsuyama | Ehime | 790-0067 | Japan |
| Chikushino-shi | Fukuoka | 818-8516 | Japan |
| Amagasaki | Hyōgo | 660-8550 | Japan |
| Kobe | Hyōgo | 650-0047 | Japan |
| Kobe | Hyōgo | 654-0155 | Japan |
| Higashiibaraki | Ibaraki | 311-3193 | Japan |
| Hiratsuka | Kanagawa | 254-8502 | Japan |
| Kawasaki | Kanagawa | 211-8533 | Japan |
| Yokohama | Kanagawa | 245-8575 | Japan |
| Uji | Kyoto | 611-0041 | Japan |
| Sendai | Miyagi | 983-8520 | Japan |
| Naha | Okinawa | 900-0005 | Japan |
| Naha | Okinawa | 902-8511 | Japan |
| Urasoe | Okinawa | 901-2132 | Japan |
| Sayama | Saitama | 350-1305 | Japan |
| Kusatsu | Shiga | 525-8585 | Japan |
| Shinjuku-ku | Tokyo | 162-8655 | Japan |
| Shinjuku-ku | Tokyo | 162-8666 | Japan |
| Kofu | Yamanashi | 400-8506 | Japan |
| Fukuoka | 810-0001 | Japan |
| Kagoshima | 892-0853 | Japan |
| Kyoto | 607-8062 | Japan |
| Okayama | 700-8607 | Japan |
| Osaka | 558-8558 | Japan |
| Shizuoka | 420-8630 | Japan |
| ID | Term |
|---|---|
| D006333 | Heart Failure |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C576501 | finerenone |
| D000077545 | Eplerenone |
| ID | Term |
|---|---|
| D007783 | Lactones |
| D009930 | Organic Chemicals |
| D011283 | Pregnenes |
| D011278 | Pregnanes |
| D013256 | Steroids |
| D000072473 | Fused-Ring Compounds |
| D011083 | Polycyclic Compounds |
Not provided
Not provided